journal
https://read.qxmd.com/read/35081305/janus-kinase-and-tyrosine-kinase-inhibitors-in-dermatology-a-review-of-their-utilization-safety-profile-and-future-applications
#21
REVIEW
Mojahed M K Shalabi, Benjamin Garcia, Kendall Coleman, Alfredo Siller, Austinn C Miller, Stephen K Tyring
Janus kinase inhibitors, also commonly referred to as JAK inhibitors, are a novel drug class that target and block cytokine signaling mediated by the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, thereby regulating immune response and cell growth. Although JAK inhibitors are mainly used for rheumatological conditions such as rheumatoid arthritis, their application in the field of dermatology is actively being investigated. Tofacitinib is US FDA-approved for psoriatic arthritis and showing promise for treating psoriasis...
January 2022: Skin Therapy Letter
https://read.qxmd.com/read/35081302/topical-clascoterone-for-acne-vulgaris
#22
JOURNAL ARTICLE
Nicole E Burma, Taylor E Woo, Laurie Parsons
The pathogenesis of acne is multifactorial and involves inflammation, bacterial dysbiosis, and androgen stimulation. Existing systemic therapies target hormonal pathways to mitigate acne lesions; however, their use is limited to the female population and associated with systemic adverse effects. Clascoterone is the first topical therapy to target the hormonal pathogenesis of acne approved to treat acne vulgaris. In two identical phase 3 trials, clascoterone showed favorable efficacy over placebo in treating acne, with higher treatment success and a greater reduction in acne lesions...
January 2022: Skin Therapy Letter
https://read.qxmd.com/read/34871479/psoriasis-education-tool-for-patient-physician-decision-making-about-biologics-a-pilot-study
#23
JOURNAL ARTICLE
Marissa Nahirney, Matthew Hum, Pamela Mathura, Marlene Dytoc
Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment. We used a quality improvement approach to develop and trial an educational visual aid to deliver comprehensive information about biologics in a convenient manner. As a pilot study, trialing this tool was carried out on a small scale to test the feasibility of both the study design and the visual aid itself, with 8 physician and 8 patients completing questionnaires evaluating the visual aid...
November 2021: Skin Therapy Letter
https://read.qxmd.com/read/34871475/fixed-combination-halobetasol-propionate-and-tazarotene-lotion-for-plaque-psoriasis
#24
JOURNAL ARTICLE
Lyn Guenther, Andrei Metelitsa, Vimal H Prajapati
A novel fixed combination lotion containing the super-potent corticosteroid halobetasol propionate 0.01% and retinoid tazarotene 0.045% (Duobrii™) has recently been introduced and indicated for the treatment of moderate to severe plaque psoriasis in adults. Studies have shown that there is synergy between the ingredients and that the product can be safely used intermittently for up to 1 year. Treatment success (i.e., Investigator Global Assessment [IGA] of clear/almost clear [IGA 0/1] and at least a 2-grade improvement from baseline) occurred in 58...
November 2021: Skin Therapy Letter
https://read.qxmd.com/read/34524781/hair-removal-practices-a-literature-review
#25
REVIEW
Cindy Na-Young Kang, Monica Shah, Charles Lynde, Patrick Fleming
Hair removal practices have evolved from adhering to social, cultural, and religious traditions to meeting aesthetic standards. Hair removal methods can be divided into two categories: 1) depilation, which involves removing the hair shaft and includes shaving and chemical depilatories, and 2) epilation, which involves removing the hair shaft, follicle, and bulb, and includes plucking, threading, waxing, sugaring, lasers, intense pulsed light system, electrolysis, and photodynamic therapy. Furthermore, an eflornithine hydrochloride 13...
September 2021: Skin Therapy Letter
https://read.qxmd.com/read/34524780/labeling-laws-for-personal-care-products-potential-pitfalls-for-the-consumer
#26
JOURNAL ARTICLE
Evelyne Tantry, Ariadna Perez-Sanchez, Shelly Fu, Shravya Potula, Rajani Katta
Consumers of personal care products must be made aware of the potential pitfalls that arise from current labeling practices and regulations. For example, terms such as "hypoallergenic", "sensitive skin", and "baby product" lack legal definitions, and terms such as "fragrance-free" are frequently misinterpreted. Personal care products are a general category that includes such items as cosmetics, drugs, dietary supplements, and consumer goods. This overview of current US FDA regulations of products in this category reviews pertinent regulatory policies and highlights potential consumer pitfalls when evaluating product labels...
September 2021: Skin Therapy Letter
https://read.qxmd.com/read/34347397/moisturizers-and-cleansers-in-the-management-of-skin-conditions-caused-by-personal-protective-equipment-and-frequent-handwashing
#27
REVIEW
Sara Mirali, Patrick Fleming, Charles W Lynde
During the COVID-19 pandemic, prolonged usage of personal protective equipment (PPE) and frequent handwashing has exacerbated or caused skin diseases, particularly amongst frontline workers. Skin conditions, such as atopic dermatitis, irritant contact dermatitis, and hand eczema, affect patients’ quality of life and their ability to work. These conditions can be managed by frequent moisturization and washing with gentle cleansers. In this review, we discuss the properties of effective moisturizers and cleansers for patients with skin diseases related to enhanced infection control procedures...
July 2021: Skin Therapy Letter
https://read.qxmd.com/read/34347259/rosacea-an-update-in-diagnosis-classification-and-management
#28
JOURNAL ARTICLE
Cindy Na-Young Kang, Monica Shah, Jerry Tan
The diagnosis and classification of rosacea has been modified to reflect presenting features. On exclusion of differentials, the diagnosis of rosacea is based on the presence of either (1) phymatous changes, or (2) centrofacial persistent erythema. In their absence, diagnosis can be established by presence of any two of: flushing/transient erythema, papules and pustules, telangiectases, or ocular manifestations. Management of rosacea depends on presenting feature(s), their severity, and impact. General management includes gentle skin care, sun protection, and trigger avoidance...
July 2021: Skin Therapy Letter
https://read.qxmd.com/read/34077168/prurigo-nodularis-review-and-emerging-treatments
#29
REVIEW
Maria Leis, Patrick Fleming, Charles W Lynde
Prurigo nodularis (PN) is a chronic, recalcitrant inflammatory skin condition characterized by the presence of pruritic nodules. The exact pathogenesis of the disease is unknown, although immune and neural dysregulation are indicated in driving the itchscratch cycle. Specifically, interleukin-4 and interleukin-31 pathways have been recently implicated in transmission of the pruritic sensation. There are currently no US FDA-approved targeted therapies for the treatment of PN. This article aims to review our present understanding of the disease pathogenesis and treatments, with a focus on emerging therapeutics...
May 2021: Skin Therapy Letter
https://read.qxmd.com/read/34077151/bimekizumab-for-moderate-to-severe-plaque-psoriasis
#30
JOURNAL ARTICLE
Ryan D Gotesman, Ron Vender
Psoriasis is an immune-mediated inflammatory skin disease that affects about 2% of the population and is associated with many comorbidities. Recent advances have demonstrated interleukin (IL)-17 signaling plays a crucial role in the pathogenesis of psoriasis. Bimekizumab is a novel monoclonal antibody treatment for psoriasis that uses a single binding site to inhibit IL-17A and IL-17F. Here we will discuss the safety and efficacy of bimekizumab in the treatment of moderate-to-severe plaque psoriasis.
May 2021: Skin Therapy Letter
https://read.qxmd.com/read/33769773/utility-of-the-human-papillomavirus-vaccination-in-management-of-hpv-associated-cutaneous-lesions
#31
JOURNAL ARTICLE
Jane Gay, Nathan Johnson, Varun Kavuru, Mariana Phillips
Human papillomavirus (HPV)-induced cutaneous disease is a common complaint for patients presenting for dermatology evaluation. Infection by HPV is the major etiologic factor in the development of cutaneous warts, epidermodysplasia verruciformis, and possibly a subset of cutaneous squamous cell carcinoma. Carcinoma of the genitourinary tract, most notably cervical carcinoma, is the most severe manifestation of infection with specific serotypes of HPV. For this reason, the HPV immunization (Gardasil) was developed in 2006 and upgraded in 2018 to a nonavalent formulation that includes serotypes 6, 11, 16, 18, 31, 33, 45, 52, 58...
March 2021: Skin Therapy Letter
https://read.qxmd.com/read/33769772/certolizumab-pegol-in-plaque-psoriasis-considerations-for-pregnancy
#32
REVIEW
Jeremy Strain, Maria Leis, Kyle O Lee, Patrick Fleming
Psoriasis is a chronic, immune-mediated skin condition which commonly affects women of childbearing age. Certolizumab pegol (CZP) is an anti-tumor necrosis factor-alpha (anti-TNFα) agent that has demonstrated long-term safety and efficacy in treating moderate-to-severe plaque psoriasis. Previously, there has been limited safety data surrounding its use in pregnancy. The objective of this article is to review pivotal clinical trial data for CZP and explore safety considerations for this agent in pregnancy. This review demonstrates that CZP offers a safe and effective treatment option for women during childbearing years based on pharmacokinetics and available safety data...
March 2021: Skin Therapy Letter
https://read.qxmd.com/read/33539062/long-term-efficacy-and-safety-of-once-daily-efinaconazole-10-topical-solution-jublia-for-dermatophyte-toenail-onychomycosis-an-interim-analysis
#33
RANDOMIZED CONTROLLED TRIAL
Aditya K Gupta, Elizabeth A Cooper
Onychomycosis, a difficult-to-treat fungal nail infection, is more prevalent in the elderly. Efinaconazole 10% topical solution is a firstline therapy for onychomycosis, based on phase III trials of 12-month treatment; the slow growth of onychomycotic nails suggests a longer treatment period may increase efficacy. This is the first efficacy and safety data for a 24-month duration of efinaconazole 10% topical solution treatment for onychomycosis. Enrolled patients (N = 101) with mild to moderate distal lateral subungual onychomycosis applied efinaconazole to all affected toenails once daily for 18-24 months...
January 2021: Skin Therapy Letter
https://read.qxmd.com/read/33539061/crisaborole-2-ointment-for-mild-to-moderate-atopic-dermatitis
#34
JOURNAL ARTICLE
Aryan Riahi, Joseph M Lam
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory condition marked by pruritus and traditionally treated with topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI). Crisaborole 2% ointment (a topical phosphodiesterase-4 inhibitor) is a newer topical agent for the treatment of AD. Crisaborole is indicated for treating mild-to-moderate AD and evidence from phase 3 and phase 4 trials show that crisaborole is an effective agent with a well-tolerated side effect profile for children >2 years of age...
January 2021: Skin Therapy Letter
https://read.qxmd.com/read/33196157/nicotinamide-an-update-and-review-of-safety-differences-from-niacin
#35
JOURNAL ARTICLE
Reed Huber, Aaron Wong
Nicotinamide (or niacinamide), a form of vitamin B3 that is often confused with its precursor nicotinic acid (or niacin), is a low-cost, evidence-based oral treatment option for actinic keratosis, squamous cell carcinomas, basal cell carcinomas, and bullous pemphigoid. Despite its favorable safety profile and affordability, the integration of nicotinamide into clinical practice is an ongoing process, and like many over-the-counter supplements it has faced some barriers. The purpose of this article is to address some of those barriers by reviewing its efficacy, safety profile, and emphasizing the difference between nicotinamide and niacin...
November 2020: Skin Therapy Letter
https://read.qxmd.com/read/33196156/pediatric-psoriasis-comorbidities
#36
JOURNAL ARTICLE
Nicole W Kittler, Kelly M Cordoro
While the association between psoriasis and various comorbidities is well documented in adults, questions remain as to whether the same relationships exist in the pediatric population. However, psoriasis develops in childhood or adolescence in approximately 40% of patients, suggesting that the risk of comorbidities may also begin early in life. This presents an opportunity for prevention, early detection and intervention for children who may suffer from, or be at risk of, comorbidities. The pediatric psoriasis Comorbidity Screening Initiative, a multidisciplinary panel, devised and published consensus-based screening recommendations for pediatric psoriasis patients in 2017...
November 2020: Skin Therapy Letter
https://read.qxmd.com/read/33017108/dermatologic-applications-and-safety-considerations-of-janus-kinase-inhibitors
#37
REVIEW
Steven A Svoboda, Nathan Johnson, Mariana Phillips
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, represent a new class of medication that have broad potential to treat dermatologic disease. Currently, the only FDA-approved dermatologic indication for this class of medications is psoriatic arthritis; however, their utility in treating other immune-mediated skin conditions including atopic dermatitis, vitiligo, alopecia areata, and systemic and cutaneous lupus is actively being investigated. Overall, these drugs appear to be well-tolerated and have a safety profile similar to that of other biologics commonly used in dermatologic practice, although an increased risk of thromboembolism has been associated...
September 2020: Skin Therapy Letter
https://read.qxmd.com/read/33017107/elective-treatment-of-dermatosis-papulosa-nigra-a-review-of-treatment-modalities
#38
JOURNAL ARTICLE
Mimi Tran, Vincent Richer
Dermatosis papulosa nigra is a benign skin lesion found most frequently on the face of patients with skin of color. Elective treatment is occasionally requested. However, in view of knowledge gaps regarding aesthetic treatments for skin of color, patients can be exposed to unnecessary risks or simply denied treatment options due to physician reservation. Cosmetic treatments should balance efficacy of lesion removal while minimizing pigmentary complications. In this review, we describe the few published treatment modalities for dermatosis papulosa nigra...
September 2020: Skin Therapy Letter
https://read.qxmd.com/read/32510891/management-of-primary-small-vessel-vasculitis
#39
REVIEW
Crystal E Nwannunu, Radhika Shah, Allison L Limmer
Small-vessel vasculitides (SVV) are a group of disorders that occur due to primarily systemic inflammation or as sequelae of an infection, malignancy, or other rheumatic disease. Arising in any organ including the skin, the clinical features of SVV encompass a variety of manifestations. A comprehensive diagnostic assessment should be performed as management protocols widely differ. Although rare, physicians should be familiar with the common types of SVV to ensure prompt management and prevention of severe, life-threatening end-organ damage...
May 2020: Skin Therapy Letter
https://read.qxmd.com/read/32510689/risankizumab-an-il-23p19-inhibitor-for-psoriasis-a-review-of-the-current-literature
#40
JOURNAL ARTICLE
Julian McDonald, Khalad Maliyar, Melinda J Gooderham
Psoriasis is a common, chronic, immune-mediated, inflammatory disorder with significant skin manifestations and substantial burden on quality of life. Interleukin-23 is a key regulator of different effector cytokines and plays a cardinal role in the pathogenesis of psoriasis. The monoclonal antibody, risankizumab, inhibits this key cytokine and thus prevents the downstream inflammatory cascade. This article aims to review our current understanding of risankizumab through the analysis of the various clinical trials...
May 2020: Skin Therapy Letter
journal
journal
34395
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.